Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified - between 25 September 2014 and 1 September 2016

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and advertising of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. The Act was introduced to address the need for a comprehensive regulatory framework that governs therapeutic goods, including medicines, medical devices, and other health-related products. The Therapeutic Goods Act 1989 is administered by the Therapeutic Goods Administration (TGA), an agency of the Australian Government's Department of Health. The policy objective of the Act is to protect the public's health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. The 2014 consent provided by the delegate of the Secretary of the Department of Health for AbbVie Pty Ltd to import and supply beractant (SURVANTA) addresses a specific issue with the labelling of the product, allowing for a temporary exemption from certain labelling requirements to facilitate a smooth transition during a change in sponsorship. The consent granted under section 14 and 14A of the Therapeutic Goods Act 1989 permits the importation and supply of beractant (SURVANTA) with labelling that does not conform to certain requirements, specifically addressing the presence of the previous sponsor's address and name on the product's labelling. This consent is effective from September 25, 2014, until September 1, 2016, and is subject to specific conditions to ensure continued compliance with other aspects of the Act, such as maintaining customer service provisions and ensuring proper communication channels are established. This measure was introduced to address a transitional issue in the sponsorship of the product, ensuring that the public's health is not compromised during the period of change.

Scope and Application

The Therapeutic Goods Act 1989, as amended, pertains to the regulation of therapeutic goods in Australia, and its scope encompasses a wide range of products including medicines, medical devices, and blood and blood components. The Act applies to persons and entities involved in the import, supply, and manufacturing of therapeutic goods, including pharmaceutical companies, medical device manufacturers, and healthcare providers. The Act's jurisdictional reach is national, as it is a Commonwealth Act, thereby applying across all states and territories within Australia. The Act establishes a comprehensive regulatory framework, including requirements for the quality, safety, efficacy, and labelling of therapeutic goods. In certain circumstances, the Act allows for exemptions or alternative arrangements, such as the consent given for the importation and supply of specific batches of beractant (SURVANTA) that do not conform to certain labelling requirements. This particular consent, issued under sections 14 and 14A of the Act, highlights the flexibility of the regulatory framework to accommodate exceptional circumstances while maintaining the overarching objective of protecting public health. The Act also provides for the creation of therapeutic goods regulations and orders, which can further refine and extend the application of the Act through subordinate legislation.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") plays a crucial role in regulating the importation, supply, and labelling of therapeutic goods in Australia. Section 14 of the Act allows the delegate of the Secretary of the Department of Health to give consent to the importation and supply of therapeutic goods that do not conform with certain regulatory requirements. In this case, section 14A of the Act is particularly relevant as it pertains to the labelling of medicines. On September 25, 2014, the delegate provided consent under this section for AbbVie Pty Ltd to import and supply beractant (SURVANTA) 200 mg/8 mL suspension vials (AUST R 48406), which do not comply with clause 3(2)(l) of the Therapeutic Goods Order No. 69 concerning general requirements for labels for medicines. This consent allows the continued supply of these products despite the non-conformance of the labelling. Under the Act, the obligations imposed on the parties involved are stringent. AbbVie Pty Ltd must ensure that the labelling of the supplied products adheres to the conditions set by the delegate of the Secretary. Specifically, the labelling must contain the previous address of the sponsor (32-34 Lord St, Botany, NSW 2019) and the previous sponsor name Abbott. Furthermore, AbbVie Pty Ltd is required to have arrangements in place to forward materials sent to the previous address to the current sponsor address. Additionally, services such as medical information, customer enquiries, pharmacovigilance activities, and customer complaints must continue to be provided. Contingencies must also be established to ensure that any communications with the previous address are appropriately redirected to the new address. Failure to comply with the conditions set out in the consent may result in significant legal consequences. The Act does not explicitly state the specific offences or penalties for non-compliance in this context, but generally, breaches of the Therapeutic Goods Act can lead to civil and criminal penalties. Civil penalties can include fines, and in severe cases, criminal penalties can include imprisonment. The exact penalties would depend on the nature and severity of the breach, as outlined in other sections of the Act and relevant regulations. It is imperative that AbbVie Pty Ltd adheres strictly to the conditions to avoid any legal ramifications.